FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents a method of treating acid sphingomyelinase (asmd) deficiency in a human subject, involving administering recombinant human acid sphingomyelinase (rhasm) to a human subject in a dose-increasing regimen.
EFFECT: invention provides higher clinical effectiveness in acid sphingomyelinase deficiency.
30 cl, 7 dwg, 9 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ENZYME REPLACEMENT THERAPY WITH DOSE INCREASE FOR TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY | 2010 |
|
RU2569744C2 |
| ENZYMATIC REPLACEMENT THERAPY WITH DOSE INCREASE FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | 2010 |
|
RU2731616C2 |
| TREATMENT OF PATHOLOGICAL BONE CONDITIONS IN PATIENTS WITH ACID SPHINGOMYELINASE DEFICIENCY | 2018 |
|
RU2795570C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | 2019 |
|
RU2826120C2 |
| TREATMENT OF CORONAVIRUS INFECTION | 2021 |
|
RU2837859C1 |
| IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | 2020 |
|
RU2822089C2 |
| METHODS OF TREATING CHOLESTASIS | 2020 |
|
RU2829466C2 |
| METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS | 2020 |
|
RU2828027C2 |
| USE OF CALCIFEDIOL IN PATIENTS UNDERGOING BARIATRIC SURGERY | 2019 |
|
RU2837000C2 |
| INTRODUCTION OF ANTISENSE OLIGINUCLEOTIDES, COMPLEMENTARY TO HUMAN APOLYPOPROTEIN B | 2008 |
|
RU2559536C2 |
